News | Stent Grafts | June 13, 2018

FDA Committee Votes in Favor of Incraft AAA Stent Graft System

Cardinal Health device designed for the endovascular treatment of infrarenal abdominal aortic aneurysms

FDA Committee Votes in Favor of Incraft AAA Stent Graft System

June 13, 2018 — Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable recommendation on its premarket approval application from a key U.S. Food and Drug Administration (FDA) panel. The FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee voted 11 to 4 in favor of the benefits of the device.

The Incraft system is an advanced endovascular aneurysm repair (EVAR) technology for the treatment of infrarenal abdominal aortic aneurysms (AAAs), a severe and complex condition.

An abdominal aortic aneurysm is a bulging, weakened area in the wall of the lower part of the aorta, the main artery of the body, which, unless treated, can rupture and lead to a life-threatening hemorrhage. An estimated 1.5 million people in the United States have AAA, and more than 200,000 new diagnoses are made each year.1 These aneurysms account for approximately 10,000 deaths annually in the United States.2 Once identified, treatment options for AAAs include medical monitoring, open surgical repair or EVAR, a minimally invasive endovascular treatment option with the potential to reduce perioperative mortality and morbidity.

While several EVAR devices are currently available in the U.S., treatment options are limited for many AAA patients with small femoral or iliac arteries or with heavily calcified or tortuous vessels that could lead to complications during the introduction of EVAR devices.

The Incraft system is an ultra-low profile and flexible stent-graft system designed to prevent rupture of infrarenal AAAs in a wide range of patient populations.

The favorable vote of the advisory committee followed a review of clinical data from the pivotal INSPIRATION trial. The prospective, multi-center, single-arm study evaluated the safety and effectiveness of the Incraft system in patients with AAA. The trial showed that the Incraft system met the primary safety and effectiveness endpoints, with a low rate of major adverse events at 30 days and a high rate of successful aneurysm treatment at 1 year.3 As presented at the Circulatory System Devices Panel meeting, the trial demonstrated high survival of nearly 80 percent and no aneurysm ruptures through four years of follow up.

The Incraft system, which received a CE mark in 2014, is commercially available in 39 countries. It is an investigational device not available for sale in the United States.


For more information:



1. Lifetime Risk and Risk Factors for Abdominal Aortic Aneurysm in a 24 Year Prospective Study: the ARIC Study. Atherosclerosis, Thrombosis, and Vascular Biology. 2016;36:2468-2477

2. Centers for Disease Control and Prevention (CDC), 2017

3. Ohki, One-Year Outcomes of the INSPIRATION Study of the INCRAFT® Stent-Graft System for Treatment of Abdominal Aortic Aneurysms (AAAs), Society for Vascular Surgery 2015

Related Content

Obese Patients Have More Post-Op Problems Following AAA Repair
News | Endovascular Aortic Repair | November 21, 2018
New research in the December edition of the Journal of Vascular Surgery suggests significant increase in morbidities in...
FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall
News | Endovascular Aortic Repair | October 08, 2018
Endologix Inc. received notice that the U.S. Food and Drug Administration (FDA) has classified a voluntary recall...
The Gore TAG stent graft used in TEVAR aortic repair procedures for aneurysms.

The Gore TAG stent graft used for endovascular aortic aneurysm repair procedures.

Feature | Endovascular Aortic Repair | February 05, 2018 | Andrei Churyla, M.D., S. Chris Malaisrie, M.D.
Here are several considerations for physicians when choosing...
Endologix Receives IDE Approval for EVAS2 Confirmatory Clinical Study
News | Endovascular Aortic Repair | October 19, 2017
Endologix Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA...
New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair
News | Endovascular Aortic Repair | May 23, 2017
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and...
abdominal aortic aneurysm, AAA, gender differences, women vs. men, endovascular repair, Journal of Vascular Surgery study
News | Endovascular Aortic Repair | April 05, 2017
Following repair of abdominal aortic aneurysms (AAA), women appear to have more unfavorable outcomes than men in terms...
Beaumont Hospital, Michigan, endovascular aortic repair, EVAR, conscious sedation
News | Endovascular Aortic Repair | July 08, 2016
Kirk Schoenherr, 56, of Clinton Township, Mich., recently became just the second patient at Beaumont Hospital, Royal...
Aptus Endosystems, Medtronic, acquisition, Heli-FX, Thoracic EndoAnchor, EVAR

Heli-FX image courtesy of Aptus Endosystems

News | Endovascular Aortic Repair | July 02, 2015
Medtronic plc announced it has acquired the assets of Aptus Endosystems Inc., a privately held medical device company...
Overlay Init